Compass Pathways Plc Stock Price, News & Analysis

COMPASS Pathways (Nasdaq: CMPS) announced funding for the first study exploring the effects of COMP360 psilocybin on brain pathways in autistic adults. The double-blind, randomized, placebo-controlled study, named PSILAUT, will assess serotonin brain network differences between autistic and non-autistic individuals. Conducted at King's College London, it will involve 70 participants, including 40 with autism. Professor Grainne McAlonan leads the research, aiming to enhance treatment options for autism by understanding underlying brain mechanisms.

COMPASS Pathways plc (Nasdaq: CMPS) announced it will release its financial results for Q1 2022 and provide a business update on May 10, 2022. The management will host a conference call at 8:00 AM ET. The call will also be accessible via webcast and archived for 30 days. COMPASS is focused on mental health innovations using its synthetic psilocybin formulation, COMP360, which has received FDA Breakthrough Therapy designation for treatment-resistant depression. The company recently completed a Phase IIb clinical trial, showing statistically significant improvements in depressive symptoms.

COMPASS Pathways (Nasdaq: CMPS) presented positive data on COMP360 psilocybin therapy in two investigator-initiated studies at the Society of Biological Psychiatry Annual Meeting in New Orleans. The first study involved 12 patients with severe treatment-resistant depression, reporting a 58.3% response rate and no serious adverse events. The second study with 10 anorexia nervosa patients showed 30% achieving significant reductions in symptoms at one-month follow-up. Both studies demonstrated the therapy's potential, supporting further investigation in larger clinical trials.

COMPASS Pathways reported positive results from its phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression, showing rapid and sustained patient response with a single 25mg dose. Additionally, an open-label study indicated effectiveness when combined with SSRI antidepressants. The company is well-capitalized with a cash position of $273.2 million at year-end 2021. The end-of-phase II meeting with the FDA is scheduled for April 2022, with a phase III program expected to start in the second half of the year. New senior executives have also been appointed.

COMPASS Pathways (Nasdaq: CMPS), a mental health care company, is set to release its financial results for Q4 and the entire year of 2021, along with an update on recent developments, on February 24, 2022. A conference call will follow at 8:00 AM ET, accessible via phone and webcast. COMPASS is pioneering a new model of psilocybin therapy, recently achieving significant results in a large-scale clinical trial for treatment-resistant depression.

COMP360, its breakthrough therapy, is currently in further clinical trials for PTSD.

COMPASS Pathways plc (CMPS) has announced positive results from a phase I study on COMP360 psilocybin therapy, demonstrating its feasibility in simultaneous administration to healthy participants under 1:1 therapist support. Conducted by King's College London, the study involved 89 participants receiving different doses of psilocybin or placebo, with no serious adverse effects reported. The findings suggest potential for psilocybin therapy in treating severe mental health issues, paving the way for upcoming FDA discussions and plans for a phase III trial expected to begin in Q3 2022.

COMPASS Pathways (Nasdaq: CMPS) announced its addition to the Nasdaq Biotechnology Index, effective December 20, 2021. This index tracks biotech and pharmaceutical securities, making it significant for institutional investors. CEO George Goldsmith expressed pride in this achievement, which aims to enhance visibility as the company advances its COMP360 psilocybin therapy for mental health. This therapy has received FDA Breakthrough Therapy designation for treatment-resistant depression and has shown statistically significant clinical trial results.

COMPASS Pathways (Nasdaq: CMPS) has appointed Matthew Owens as its new General Counsel and Chief Legal Officer, effective February 1, 2022. Owens joins from Novartis, where he was the Global Head of Legal, Digital. Concurrently, Lars Wilde, co-founder and Chief Business Officer, will transition to a senior advisory role from January 1, 2022. Under Wilde's leadership, COMPASS raised over $429 million and advanced its psilocybin therapy for mental health, which has received Breakthrough Therapy designation from the FDA.